The U.S. Department of Justice (DOJ), through the Drug Enforcement Administration (DEA), has issued a final order rescheduling certain marijuana-related products from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift represents a significant federal policy change that long term care providers should understand. What Does This Mean?
This change mainly applies to:
- FDA-approved marijuana-based medications
- Marijuana products used under state medical cannabis programs
These products are now recognized as having medical use and a lower risk level than before.
Why This Matters for You
For long term care providers, this could impact how certain medications are handled:
- Prescribing: Providers may see increased use of cannabis-based medications, like Marinol (currently Schedule III), Syndros/dronabinol and Epidiolex (hemp-derived), prescribed by practitioners. However, for state-approved cannabis products, obtaining these products follows state-specific rules.
- Compliance: These products will still be regulated, so facilities must follow rules similar to other controlled medications.
- Documentation & Storage: Proper recordkeeping, storage, and security requirements will apply.
State Laws Still Apply
State medical marijuana programs remain important. If your state allows medical cannabis, those rules still guide how products are used in your facility. Note that state laws and regulations governing medical marijuana can vary significantly from state-to-state.
What You Should Do Now
- Review your medication policies and procedures
- Talk with your pharmacy and medical director
- Train staff on handling controlled substances
- Stay updated on both federal and state requirements
Bottom Line
This change does not fully legalize marijuana, but it may increase access to certain cannabis-based medications. Providers should be prepared to manage these products safely and in compliance with laws and regulations.